Posted by Michael Wonder on 08 Nov 2025
Novo Nordisk announces agreement with the US Administration to bring GLP-1s to more Americans at a lower cost
6 November 2025 - Today it was announced that Novo Nordisk has agreed with the US Administration to lower drug prices beginning in 2026 and expand patient access and affordability for semaglutide medicines, including Wegovy and Ozempic, in US Medicare Part D and Medicaid and in direct to patient cash channel.
Medicare Part D coverage for anti-obesity medicines will be enabled through a pilot program designed to cover a majority of Part D beneficiaries.
In addition, Novo Nordisk is expected to receive a three year tariff exemption.
